Silk Cotton Root (Semal Musli) and the Reproductive-Tonic Claim

The dried, powdered root of a young Bombax ceiba sapling — sold as semal musli — is marketed across the Indian herbal trade as a male reproductive tonic. This page treats that specific claim on its own, separately from the tree's other parts: the flower, the bark and the gum have their own distinct research, covered on their own pages, and none of it transfers here. Root evidence means root evidence, and for this claim it comes down to exactly one controlled study.

Table of Contents

  1. The Traditional Claim: Semal Musli as a Vrishya / Vajikarana Drug
  2. What "Semal Musli" Actually Is
  3. The One Controlled Study: Bhargava, Thakur and Yadav, 2012
  4. Reading That Study Correctly
  5. Mechanism Plausibility: What Is Actually in the Root
  6. A Different Root Claim: Antibacterial and Enzyme-Inhibition Screening
  7. The Identity Problem: Semal Musli as a Safed Musli Substitute
  8. A Name That Already Asserts the Outcome
  9. Erectile Dysfunction Is a Medical Signal, Not Just a Symptom to Treat
  10. Cautions and Practical Guidance
  11. Key Research Papers
  12. Connections

The Traditional Claim: Semal Musli as a Vrishya / Vajikarana Drug

Classical Ayurvedic materia medica sorts drugs by therapeutic class, and one of those classes is vajikarana — literally "that which makes one like a horse," the branch concerned with sexual vigor, fertility and semen quality. A closely related classical term, vrishya, describes a substance credited with increasing virility and reproductive potency specifically. Bombax ceiba root, dried and powdered as semal musli, is classed among the vrishya / vajikarana drugs in traditional texts, alongside better-known names such as ashwagandha, shatavari and safed musli (a different plant entirely — see below).

The traditional use is old and the classification is real. Neither fact tells you whether the root does anything measurable in a living person. That is a separate question, answered separately below.

Back to Table of Contents

What "Semal Musli" Actually Is

Semal musli is the fleshy taproot of a one- to two-year-old Bombax ceiba sapling, dug up, washed, dried and powdered. It is not the root of a mature tree — by the time a silk cotton tree is old enough to flower, its taproot has woodened past the soft, starchy consistency the trade wants. This matters because it means the material is harvested destructively from young trees, before they reach reproductive age themselves, which is a real sustainability concern for wild-collected stock, separate from any question about whether it works.

The name "musli" is shared with a completely unrelated plant, Chlorophytum borivilianum (safed musli, "white musli"), which carries the same category of reproductive-tonic claim and is the more expensive, more prestigious material in the trade. Bombax ceiba root is sometimes called "red musli" or sold simply as "musli" without qualification, and the identity confusion this creates is its own hazard, covered in its own section below.

Back to Table of Contents

The One Controlled Study: Bhargava, Thakur and Yadav, 2012

Searching PubMed for Bombax ceiba against every term that could plausibly capture a reproductive or sexual-function claim — aphrodisiac, spermatogenesis, testosterone, fertility, androgenic, sexual behavior, libido — returns exactly one controlled study. It deserves to be described precisely rather than waved at, because precision is what a single study can actually support.

The study. Bhargava C, Thakur M and Yadav SK, published in Andrologia in 2012, titled "Effect of Bombax ceiba L. on spermatogenesis, sexual behaviour and erectile function in male rats." A lyophilised (freeze-dried) aqueous extract of young Bombax ceiba roots — explicitly semal musli, described in the paper's own introduction as the traditional sexual-stimulant material — was administered to male albino rats at 100 mg/kg body weight, with a control group receiving no extract.

What was measured, and what was found:

That mixed result — several behavioral and reproductive-tissue parameters reaching significance, while the single most marketable number, testosterone, did not — is worth sitting with rather than smoothing over. A supplement listing built from this paper would very likely lead with "boosts testosterone." The paper itself does not support that specific sentence.

Back to Table of Contents

Reading That Study Correctly

Four things temper what this single paper can carry:

  1. It is a rat study. Mount frequency and hesitation time in a rat in the presence of a receptive female are not the same measurement as libido or satisfaction in a person, and no dose-translation or human pharmacokinetic work has ever been done to say what 100 mg/kg in a 250-gram rat corresponds to in a 70-kg adult.
  2. It has never been replicated. Thirteen-plus years after publication, no second group has repeated this experiment, extended it, or attempted a human pilot. That is not proof the finding is wrong — but a single unreplicated result is a different epistemic object from a body of converging evidence, and the traditional evidence-tier language on this site treats them differently on purpose.
  3. The behavioral endpoints are the least specific ones. Mount and intromission frequency can move for reasons that have nothing to do with androgen status — general arousal, stress-axis changes, even nonspecific stimulant effects of a novel extract. The endpoints that would most directly implicate a true androgenic or fertility mechanism — testosterone, and by extension the sperm and fructose findings that depend partly on androgen status — are the ones that came back weaker or unreplicated elsewhere.
  4. Unblinded animal behavioral scoring is not immune to observer expectation. Scoring mount and intromission frequency in real time involves judgment calls, and the study report does not describe a blinded scorer. This is a general limitation of this kind of assay, not a specific accusation against this paper, but it is why a single study of this design earns caution rather than a headline.

None of this means the study is worthless. It means it is exactly one thing: a real, published, methodologically ordinary rat study with a genuinely mixed result, sitting entirely alone. That is a fair and complete description, and it is more informative than either dismissing the plant or repeating the marketing claim.

Back to Table of Contents

Mechanism Plausibility: What Is Actually in the Root

Bombax ceiba root contains lupeol, a pentacyclic triterpene present throughout the plant and widespread across the plant kingdom generally (it is also abundant in mango peel, fig latex and aloe). Lupeol has a large cell-culture and rodent literature touching anti-inflammatory and anticancer signaling, and a smaller thread has begun to examine reproductive and endocrine effects — for example, a 2026 study isolated lupeol from a completely different plant, Ochrosia elliptica, and examined its effect in a polycystic ovarian syndrome model. That result concerns a different plant, a different compound source, and a different reproductive condition (PCOS, not male fertility) — it is cited here only to establish that lupeol as a molecule is not pharmacologically inert with respect to reproductive endocrinology, not as evidence for what Bombax ceiba root does. Crediting the root with a PCOS finding made on a different plant's lupeol would be exactly the species-substitution error this site's evidence doctrine exists to catch.

The root also contains β-sitosterol, a plant sterol structurally related to cholesterol that appears across many "tonic" botanicals and has its own separate, larger, and still-mixed human evidence base for benign prostatic hyperplasia symptoms — a different claim from vajikarana, and not addressed on this page.

In short: the chemistry gives a plausible reason someone might expect an effect. It does not substitute for the effect being demonstrated in the actual plant, at an actual dose, in an actual organism more advanced than a rat.

Back to Table of Contents

A Different Root Claim: Antibacterial and Enzyme-Inhibition Screening

A completely separate 2023 paper on Bombax ceiba root deserves mention here precisely because it is easy to conflate with the reproductive-tonic story simply for sharing the word "root." Alrabie and colleagues, publishing in Natural Product Research, ran a methanol extract of Bombax ceiba roots through combined GC-MS and LC-MS metabolomic profiling and reported two unrelated findings: antibacterial activity against Staphylococcus aureus (MIC 100 µg/mL, compared with 250 µg/mL for the antibiotic ampicillin in the same assay), and enzyme-inhibition activity against α-amylase (IC50 26.91 µg/mL) and α-glucosidase (IC50 21.21 µg/mL) — both supported by molecular docking.

Two things to hold onto. First, this has nothing to do with vajikarana, testosterone or sexual function; it is antimicrobial and antidiabetic-enzyme screening, a different claim entirely, and it belongs here only because it is the other real root-specific paper this plant has. Second, α-glucosidase inhibition is not a novel mechanism — it is the mechanism of acarbose, a licensed diabetes drug with a known, modest real-world effect on HbA1c. That gives this finding a ceiling: whatever this root extract does through the same mechanism in a dish, an approved drug working the identical way in actual patients produces a modest effect, not a dramatic one. And an in-vitro MIC beating an antibiotic's MIC in the same test tube says nothing about achievable, safe systemic concentration in a person — that is a laboratory comparison, not a claim that root powder can substitute for ampicillin.

Back to Table of Contents

The Identity Problem: Semal Musli as a Safed Musli Substitute

This site's main Bombax ceiba page already flags that semal musli is a documented adulterant and substitute for safed musli (Chlorophytum borivilianum) in the Indian herbal trade — cheaper, visually similar once dried and powdered, and sold interchangeably by less careful suppliers. It is worth being specific here about what that means for evidence, because the two roots are not evidentially equal.

Chlorophytum borivilianum has its own, separate, somewhat larger preclinical literature. As one representative example: a 2024 study in the Journal of Ethnopharmacology found that an aqueous root extract of Chlorophytum borivilianum prevented deterioration of testicular function in mice and preserved human sperm function under induced oxidative stress in vitro. This is a different plant. It does not strengthen the case for Bombax ceiba root in any way — if anything, it sharpens the problem: if a buyer intends to purchase the better-evidenced root and receives semal musli instead, they are getting the thinner evidence base without knowing it, at the price of the better one.

Neither plant has strong evidence by ordinary clinical standards. But conflating them compounds an already-weak position with an identity problem layered on top.

Back to Table of Contents

A Name That Already Asserts the Outcome

"Vrishya" and "vajikarana" are not neutral descriptive labels — they are classification names that state the intended result before any testing occurs. A root sold and studied under a name that already means "makes virile" creates the same bias problem this site has flagged on other pages carrying outcome-asserting traditional names: everyone administering the extract, scoring the mount frequency, or reading the paper afterward already knows what is supposed to happen. That does not invalidate the Bhargava 2012 findings, but it is one more reason a name-asserted outcome deserves more scrutiny, not less, and one more reason a second, independently designed study would matter more here than in a neutrally-named plant.

Back to Table of Contents

Erectile Dysfunction Is a Medical Signal, Not Just a Symptom to Treat

Anyone reaching for semal musli is most often doing so because of erectile dysfunction, low libido, or general reproductive "vitality" concerns. The most important thing this page can say is not about the root at all: new erectile dysfunction in an adult man is frequently the first visible sign of vascular disease, and can precede a diagnosed cardiac event by several years. A 2026 study of comorbidity patterns found diabetes, hypertension and cardiovascular disease all contribute independently to the severity of erectile dysfunction in the population studied — consistent with a large existing literature treating erectile function as an early bellwether of vascular health generally, not merely a standalone complaint.

This matters because effective, well-evidenced treatment already exists. PDE5 inhibitors (sildenafil and related drugs) are the established first-line pharmacological option and have reshaped the treatment landscape over the past two decades — a 2026 Australian analysis of treatment trends documents exactly this shift, away from more invasive options, in the PDE5-inhibitor era. Reaching for an unverified root powder instead of getting a medical evaluation means potentially missing both a real, treatable cause and an early warning sign of something more serious.

Back to Table of Contents

Cautions and Practical Guidance

Back to Table of Contents

Key Research Papers

  1. Bhargava C, Thakur M, Yadav SK (2012). Effect of Bombax ceiba L. on spermatogenesis, sexual behaviour and erectile function in male rats. Andrologia, 44(Suppl 1):474-8. The single controlled root study this claim rests on. — PubMed
  2. Alrabie A et al. (2023). An integrative GC-MS and LC-MS metabolomics platform determination of the metabolite profile of Bombax ceiba L. root, and in silico & in vitro evaluation of its antibacterial & antidiabetic activities. Natural Product Research, 37(13):2263-2268. A different root claim entirely — antibacterial and enzyme inhibition, not reproductive. — PubMed
  3. Mararajah S et al. (2024). Chlorophytum borivilianum aqueous root extract prevents deterioration of testicular function in mice and preserves human sperm function in H₂O₂-induced oxidative stress. Journal of Ethnopharmacology. A different plant — safed musli — cited for comparison, not as Bombax evidence. — PubMed
  4. Abdel-Sattar E et al. (2026). Exploring the therapeutic potential of Lupeol isolated from Ochrosia elliptica Labill. leaves in polycystic ovarian syndrome. Naunyn-Schmiedeberg's Archives of Pharmacology. Lupeol mechanism context from a different plant entirely. — PubMed
  5. Ghantous I et al. (2026). Comorbidities of Diabetes, Hypertension and Cardiovascular Disease and Their Contribution to Erectile Dysfunction Severity in a Lebanese Sample. Maedica. Supports the "ED as vascular signal" safety point. — PubMed
  6. Gillman N et al. (2026). Temporal Trends in Intracavernosal Injection Therapy and Penile Prosthesis Implantation in the Era of Phosphodiesterase-5 Inhibitors for Erectile Dysfunction in Australia. ANZ Journal of Surgery. Documents the real, evidence-based treatment landscape. — PubMed

PubMed Topic Searches

Back to Table of Contents

Connections

Back to Table of Contents